NEWS CENTER

Position:

Group Announcement

Media reports

Group News

Great news! Shijiazhuang No.4 Pharmaceutical Group’s two new product specifications—Terbutaline Sulfate Solution for Nebulization and Peritoneal Dialysis Fluid—have successively passed the evaluation.

Category:

Group Announcement

Time：2023-04-13

In the vibrant month of April, every moment counts as innovative achievements “bloom in full splendor.” Over the past two days, Shijiazhuang No.4 Pharmaceutical Group has reaped one after another significant research and development breakthrough: On April 12, the group’s application for Terbutaline Sulfate Solution for Nebulization (1 ml: 2.5 mg) received approval for production registration from the National Medical Products Administration. This specification marks the second domestic manufacturer to be deemed as having passed the consistency evaluation. On April 13, Peritoneal Dialysis Solution (Lactate-G2.5%) became the first in China to pass the consistency evaluation, injecting new momentum into the development of the peritoneal dialysis solution market.

Great news! Shijiazhuang No.4 Pharmaceutical Group’s two new product specifications—Terbutaline Sulfate Solution for Nebulization and Peritoneal Dialysis Fluid—have successively passed the evaluation.

In the vibrant month of April, every moment counts as innovative achievements “bloom in full splendor.” Over the past two days, Shijiazhuang No.4 Pharmaceutical Group has reaped one after another significant scientific and technological breakthrough: On April 12, the group’s application for Terbutaline Sulfate Solution for Nebulization (1 ml: 2.5 mg) received approval for production registration from the National Medical Products Administration. This specification marks the second domestic manufacturer to be deemed as having passed the consistency evaluation. On April 13, Peritoneal Dialysis Solution (Lactate-G2.5%) became the first in China to pass the consistency evaluation, injecting new momentum into the development of the peritoneal dialysis solution market.

It is reported that previously, the Group’s Shijiazhuang Sihua Pharmaceutical had already obtained production approvals from the National Medical Products Administration for Terbutaline Sulfate Solution for Nebulization (2 ml: 5 mg), Terbutaline Sulfate Active Pharmaceutical Ingredient, and Terbutaline Sulfate Injection (1 ml: 0.5 mg). The recent approval of the 1 ml: 2.5 mg specification of Terbutaline Sulfate Solution for Nebulization marks a further enrichment of the Group’s product portfolio for this particular drug, creating greater opportunities to meet diversified market demands and further leverage its competitive advantages in the market.

This peritoneal dialysis solution (lactate-G2.5%) has become the first in China to pass the consistency evaluation. This follows the group’s earlier achievement in June 2022, when its peritoneal dialysis solution (lactate-G1.5%) was the first in China to receive such an evaluation. It is understood that as the group continues to expand its success in consistency evaluations for this product category, it will further strengthen and extend its peritoneal dialysis product portfolio, providing clinicians with more high-quality products for peritoneal dialysis treatment.

In recent years, Shijiazhuang Fourth Pharmaceutical Group has taken innovation as its guiding principle, continuously increasing its investment in scientific research and remaining steadfastly committed to the development and research of innovative drugs, generic drugs, specialty active pharmaceutical ingredients, and products that have undergone or are deemed to have undergone consistency evaluations. To date, the group has accumulated a total of 44 drug varieties and 57 specifications that have either passed or are considered to have passed consistency evaluations, thereby strongly supporting the company’s advancement into the high-end segments of the value chain.

Keywords:

Shijiazhuang Sihua Pharmaceutical Group’s Compound Electrolyte Injection (II) has simultaneously received approval for two specifications.

Shijiazhuang Sihua Pharmaceutical Group’s telavancin phosphate API has been approved.

Shijiazhuang Sihua Pharmaceutical Group’s Compound Electrolyte Injection (II) has simultaneously received approval for two specifications.

Shijiazhuang Sihua Pharmaceutical Group’s telavancin phosphate API has been approved.